Document ID: chunk:federal_register_of_legislation:F2021L01384:reg:9:p2
Version: federal_register_of_legislation:F2021L01384
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 6824–9647

liver tumours, within the 1 year before the clinical onset of chronic gastropathy;
(3)          having reflux of bile acids into the stomach at the time of the clinical worsening of chronic gastritis or chronic gastropathy;
            Note: Examples of circumstances in which reflux of bile acids into the stomach can occur include post-gastrectomy, post-biliary surgery and decreased gastric or duodenal motility.
(4)          taking a non-topical, non-steroidal, anti-inflammatory drug, including aspirin, on more days than not for a continuous period of at least 8 days, within the 30 days before the clinical worsening of chronic gastritis or chronic gastropathy;
(5)          taking a drug from the Specified List 2 of drugs at the time of the clinical worsening of chronic gastritis or chronic gastropathy;
Note: Specified List 2 of drugs is defined in the Schedule 1 - Dictionary.
(6)          consuming an average of at least 350 grams of alcohol per week for at least the 6 months before the clinical worsening of chronic gastritis or chronic gastropathy;
            Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.
(7)          undergoing a course of therapeutic radiation for cancer, where the stomach was in the field of radiation, within the 1 year before the clinical worsening of chronic gastritis or chronic gastropathy;
(8)          having received yttrium-90 microspheres as therapy for primary and metastatic liver tumours, within the 1 year before the clinical worsening of chronic gastritis or chronic gastropathy;
(9)          for chronic gastritis only:
(a)          having a Helicobacter pylori infection of the gastric mucosa before the clinical worsening of chronic gastritis;
(b)          having Helicobacter heilmannii sensu lato infection of the gastric mucosa before the clinical worsening of chronic gastritis;
Note: Helicobacter heilmannii sensu lato is defined in the Schedule 1 - Dictionary.
(c)          having an infection of the gastric mucosa from the specified list of infections at the time of the clinical worsening of chronic gastritis;
Note: specified list of infections is defined in the Schedule 1 - Dictionary.
(d)          being in an immunocompromised state as specified at the time of the clinical worsening of chronic gastritis; or
               Note: immunocompromised state as specified is defined in the Schedule 1 - Dictionary.
(e)          taking an immune checkpoint inhibitor for at least the 4 weeks before the clinical worsening of chronic gastritis;
               Note: Examples of immune checkpoint inhibitors include ipilimumab, tremelimumab, nivolumab and pembrolizumab.
(10)      inability to obtain appropriate clinical management for chronic gastritis or chronic gastropathy.